NEW YORK, Oct. 5, 2017 /PRNewswire/ -- Enhanced Healthcare Partners ("EHP"), a private equity firm focused exclusively oninvesting in the healthcare industry, has announced its investment in SCA Pharmaceuticals ("SCA"), a sterile compounding leader specializing in preparing sterile pharmaceuticals customized for hospitals, pharmacies and healthcare facilities nationwide.
SCA was founded in 2010 and over the past seven years has become a nationally recognized FDA 503B outsourcing facility specializing in providing the highest quality sterile admixture services and pre-filled oral syringes to hospital pharmacies. SCA provides these services across all therapeutic areas of pharmacy including critical care, labor and delivery, anesthesia, and pain management and maintains a wide portfolio of products, including unit dosed oral syringes and drug shortage medications.
EHP is a healthcare-focused private equity firm committed to partnering with family and founder run businesses. The Enhanced team has raised more than $700 million in committed capital, completed investments in sixteen companies and closed more than 80 add-on acquisitions driving more than 60% compound annual growth in the active portfolio. EHP professionals have more than 100 years of combined experience investing in healthcare companies and possess strong relationships and knowledge within the industry.
"The sterile compounding industry has experienced unprecedented growth amidst rising production complexities as more hospitals, pharmacies and healthcare facilities require these products and simultaneously demand the highest quality of sterility assurance," said Matt Thompson, Principal at Enhanced Healthcare Partners. "SCA is a recognized leader in the field with an uncompromising commitment to quality and compliance. We are excited to work with the company's outstanding management team to support the execution of their strategic growth and development plan."
"To accomplish our ambitious goals, we knew we needed a best in class investment partner," said Milton Boyer, Chief Executive Officer of SCA. "EHP has deep experience working with innovative healthcare companies and we are thrilled to partner with their accomplished team during such an exciting phase in the company's growth. With EHP's support, SCA is primed to continue its rapid expansion and solidify itself as an industry leader."
EHP's investment enables SCA to accelerate its growth strategy, including opening a new 90,000 square-foot manufacturing facility in Windsor, Connecticut.
About SCA Pharmaceuticals SCA Pharmaceuticals is a nationally recognized FDA 503B outsourcing facility specializing in providing the highest quality sterile admixture services to hospital pharmacies throughout the U.S. Choosing to outsource products with SCA alleviates common problems health care facilities face such as wasted product, drug shortages, time-consuming processes, compliance issues, staffing costs, and patient safety concerns. SCA's state of the art facilities exceeds USP <797> standards and meets cGMP requirements. Our very talented, experienced, and dedicated team of professionals is committed to providing the safest products for patients and outstanding service. It is our policy to create a partnership with our customers based on values, quality, innovations, and patient safety.
About Enhanced Healthcare Partners Enhanced Healthcare Partners is focused on partnering with companies exclusively in the healthcare sector, working hand in hand with company leadership to drive intelligent strategy, build great teams, and develop lasting operational infrastructure. Success in healthcare starts with the people, from managers to providers, and Enhanced investment processes builds alignment across the organization, fostering a patient centric, growth oriented culture. As seasoned experts with over 100 years of combined healthcare experience and exited investments in over 20 subsectors across the healthcare industry, the Enhanced team is focused on helping growing companies achieve their next significant milestone and beyond.
Media ContactJonathan Keehner / Ed Trissel / Julie Oakes Joele Frank, Wilkinson Brimmer Katcher 212-355-4449 email@example.com
View original content:http://www.prnewswire.com/news-releases/enhanced-healthcare-partners-announces-investment-in-sca-pharmaceuticals-300531737.html
SOURCE Enhanced Healthcare Partners
Subscribe to our Free Newsletters!
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...
Therapeutic drug monitoring is measuring drug concentrations at specific intervals in a patient's ...
Sweet's syndrome or acute febrile neutrophilic dermatosis is a skin disorder with no specific ...View All